Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Pancreatic cancer
RAS(ON) inhibitors, pan-KRAS and the long wait for a second-line standard.
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)
All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.
Indexed in Crossref
41 abstracts matching pancreatic cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 11:23 UTC. This is a keyword search, not the complete abstract book.
- 1888
- 2550
- 4992Activin A promotes PDAC progression via immunosuppression and non-canonical signalingMark B. Wiley, Jessica Bauer, Yuchen Wang, Barbara Jung
- 7330Hypoxia enhances sensitivity to RAS inhibition in PDACAnna Shevzov-Zebrun, Darius Sinha, Muhammad Bin Munim, Keene Abbott et al.
- 2150
- 3045TM4SF20 scaffolds DDR1-IRS4 signaling to drive PDAC metastasis and represents a druggable therapeutic targetXinyue Liu, Weishuai Liu, Antao Chang, Jihui Hao
- 7405Targeting cysteine cathepsins to boost gemcitabine in PDACNika Mazej Jeram, Biljana Mileva Mileva Boshkoska, Aleš Tomažič, Stanislav Gobec et al.
- 6790Myeloid IFN-γsignaling regulates immunosuppressive and fibrotic tumor microenvironment in PDAC liver metastasisTakeshi Tanaka, Elena Ivleva, Ali Savas, Katarzyna Chojnacka et al.
- 3439Albumin-bound paclitaxel induced stromal reprogramming drives PDAC resistance to AG neoadjuvant chemotherapyHaorui Li, Tiansuo Zhao, Xi Ma, Xiang He et al.
- 2899Oncolytic virus-chemotherapy combination improves control of PDAC growth and spreadBiplov Sapkota, Naveen Chintala Ramulu, Shreya Pokharel, Mohammed T. Hussain et al.
- 980Multimodal chemogenomic modeling-based drug repurposing for targeted therapy of PDACAdil Ibrahim Mohammed, Zhaowei Han, Yuanhao Huang, Zihe Meng et al.
- 4518Preclinical assessment of BT5528 anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC).Lukas Stanczuk, Assunta De Rienzo, Gavin Bennett
- 7794When stress spreads: Transmissible ER stress as a driver of immune remodeling in PDACNaveen Chintala Ramulu, Shreya Pokharel, Nishanthini Pirashanna, Basel Abuaita et al.
- 1016PHIT score integrates tumor biology to predict PDAC prognosis and therapy responseDerek Erstad, Alejandro Zulbaran y Rojas, Christy Chai, Eugene Choi et al.
- 336Modular control of Pancreatic ductal adenocarcinoma (PDAC) progression by the substrate interaction domains of ERK2.Monika Verma, Billy Truong, Sven Miller, Rachael Price et al.
- 6230Tumor nuclear uPA: A transcriptional modulator of perineural invasion in PDACYun HE, Zonghua Su, Feng Ding, Zheng Chen et al.
- 7949Pharmacologic wtIDH1 inhibition remodels the PDAC immune landscape and improves checkpoint blockade efficacyPriyashree Sunita, Shakti Pattanayak, Mehdad Zarei, Omid Hajihassani et al.
- 6497Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimizationJaeger Moore, Taylor Bargenquast, Tithi Ghosh Halder, Serina Ng et al.
- 763Bridging the translational gap: Critical TME differences between human PDAC and mouse models.Rachael Guenter, Libby A. Boykin, Khidr Kishan K. Budhwani, Brahma Mubarak K. Budhwani et al.
- 1235Exercise volume, skeletal muscle maintenance, and plasma IL-6/IL-6R in patients with PDAC.Guanshu Liu, Sumedha Pareek, Truong Lam, Nathan Parker et al.
- 5984Small molecule induced KRAS activation triggers ferroptosis in mutant KRAS expressing PDACHaiyuxin Zhu, Kartini Iskandar, Nur Syafiqah B. Suleiman, Benedict J. Leong et al.
- 2906The iRGD peptide reprograms the tumor microenvironment and potentiates immunotherapy in an advanced humanized PDAC mouse modelNorio Miyamura, Yukihito Kuroda, Kodai Suzuki, Yuki Kunisada et al.
- 1251Real-world evaluation of multimodal AI: Foundation model-driven multimodal AI for GBM, NSCLC, and PDAC.Aakash Gireesh Tripathi, Asim Waqas, Evan W. Davis, Jennifer B. Permuth et al.
- 4314Bipolar pulsed field ablation triggers local and abscopal tumor control with robust immune activation in a syngeneic PDAC modelMacKenzie Demmel, Lincoln Strickland, Khadija Turabi, Alyssa Waller et al.
- 3155Pharmacokinetic/pharmacodynamic correlation and biodistribution of Re (CO)3-phenformin compared with phenformin in murine PDAC model following equimolar intravenous dosingAmir Mohammad Gholizadeh, Fatima Dagher, Mikayla Skillman, Airong Li et al.
- 7446Inflammation and chemotherapy induce immune mimicry in PDAC and promote crosstalk between fibroblasts and tumor cellsCarson Cable, Qinlin Jiang, Kourosh Kouhmareh, Richard L. Klemke et al.
- 1982Genomic analyses of patient-derived xenografts reveal novel molecular subsets of PDAC and their association with clinical features.Chani Stossel, Rotem Tal, Rouven Hoefflin, Maria Raitses-Gurevich et al.
- 1313Circulating tumor cell (CTC) informed pipeline for rapid personalization of synergistic cytokine-armed CAR-NK cell therapy in PDAC.Yin Zou, Mubin Tarannum, Shamileh Fouladdel, Yu Zhang et al.
- 4999GFRAL is not required for PDAC tumor development and TME immune cell suppressionEmma Crockett Funk, Abasi-ama Udeme, Cynthia F. Wright, Jenna Schwesig et al.
- 2447Epigenomic liquid biopsy-based biomarkers of platinum and PARP inhibitor response in patients with germ line BRCA-associated PDAC: A pilot studyMaria Raitses-Gurevich, Gulfem Guler, Yuhong Ning, Ceyda Coruh et al.
- 1273Antitumor activity of PARPi and POLQi combination therapy in a BRCA-mutated PDAC model.Chani Stossel, Dikla Atias, Yulia Glick-Gorman, Josep Forment et al.
- 3441Androgen-driven sexual dimorphism reshapes immune crosstalk and limits immunotherapy response in PDACSonia Mecorapaj, Tenzin Passang, Fanyuan Zeng, Zihan Chen et al.
- 4637Alpha-particle radiotherapy combined with anti-CTLA-4 synergistically overcomes radioresistance and induces local and systemic antitumor immunity in PDACMarco Reis, Poliana C. Marinello, Walison Augusto da Silva Brito, Scott Bright et al.
- 2857Repeated RFA remodels the PDAC microenvironment and synergizes with CSF1R blockade and checkpoint inhibition to enhance anti-tumor immunityLincoln Strickland, Wendao Liu, Casey Van Kirk, Shwetapadma Dash et al.
- 6753AI-powered Deep Visual Proteomics (DVP) links pancreatic precursor biology to PDAC survival phenotypesJimin Min, Lisa Schweizer, Gijs Zonderland, Benson Chellakkan Selvanesan et al.
- 6199Spatially revealed malignant and microenvironment ecosystems in PanIN- and IPMN-derived PDACTengyu Zhang, Assya Legrini, Mari-Claire McGuigan, Stephan B. Dreyer et al.
- LB477Neoadjuvant chemotherapy induces clinically distinct spatial remodeling of the tumor microenvironment in PDACHyun Jung Kim, Se Hui Jeong, Sujie Lee, Jung Kyoon Choi et al.
- CT145
- 7421Palmatine modulates tumor microenvironment and improves gemcitabine efficacy in PDAC via HOXA10-STAT3 axis suppressionMeagan Marie Ybarra, Xiaoyu Yang, Siri Borra, Chia-Nung Hung et al.
- 5183High-throughput ex vivo TCR-T cells screening identifies aggrephagy-driven, therapy-resistant clones in KRAS-mutant PDACMasoumeh Eshaghi, Fei Miao, Ali Abdollahzadeh, Sixing Chen et al.
- CT303Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 studyKanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang et al.